What are the indications for anabolic osteoporosis medications in adults with established osteoporosis?

Anabolic Osteoporosis Medication Indications

Anabolic osteoporosis medications (teriparatide, abaloparatide, or romosozumab) should be used as first-line treatment in postmenopausal women and men with very high fracture risk, defined as severe or multiple vertebral fractures, or those at high risk who have failed or are intolerant to bisphosphonates. 1, 2

Primary Indications for Anabolic Therapy

Very High Risk Patients (First-Line Treatment)

• Severe or multiple vertebral fractures - This is the strongest indication 1
• Recent fracture while on antiresorptive therapy (treatment failure)
• Multiple risk factors with T-score ≤ -3.0
• FRAX 10-year risk: major osteoporotic fracture >30% or hip fracture >4.5% 2
• Glucocorticoid-induced osteoporosis at very high risk 3

High Risk Patients (Conditional First-Line or Second-Line)

• History of osteoporotic fracture with T-score ≤ -2.5
• T-score ≤ -3.0 without fracture
• Intolerance or contraindications to bisphosphonates 4
• Continued bone loss or fracture on bisphosphonate therapy 1

Specific Agent Selection

Teriparatide or Abaloparatide

• Reduces vertebral fractures by 74-87% and nonvertebral fractures by 39-46% 1
• Maximum duration: 2 years total lifetime exposure (black box warning due to rat osteosarcoma studies, though human risk appears negligible) 1, 2
• Daily subcutaneous injection
• Must be followed by antiresorptive therapy to prevent rapid bone loss 2

Romosozumab

• Reduces vertebral fractures by 73-75% at 12-24 months 2
• Dual mechanism: increases bone formation while decreasing resorption 2
• Monthly subcutaneous injection for 12 months only (anabolic effect wanes after this) 2
• Black box warning: avoid in patients with myocardial infarction or stroke within past year, or high cardiovascular risk 2
• May be superior to teriparatide for BMD gains 2

Critical Treatment Sequencing

The sequence of therapy is paramount for optimal outcomes:

Anabolic-First Approach (Preferred for High/Very High Risk)

1. Start with anabolic agent (teriparatide/abaloparatide for up to 2 years, or romosozumab for 12 months)
2. Immediately transition to antiresorptive (bisphosphonate or denosumab) - no washout period needed 2
3. Continue antiresorptive long-term to consolidate gains

Rationale: Prior bisphosphonate use blunts the anabolic response by 30-50%, particularly at the hip 2, 1. The VERO trial demonstrated teriparatide superiority over risedronate in very high-risk patients 1. Anabolic-first sequential therapy produces greater BMD gains and fracture reduction than step-therapy approaches 5, 6.

Problematic Sequences to Avoid

• Denosumab → Teriparatide: BMD decreases for 6-12 months after switching 2
• Stopping denosumab without transition: Risk of rebound vertebral fractures 1
• Stopping anabolic without antiresorptive: Rapid bone loss within 1 year 1

Contraindications

Absolute contraindications to teriparatide/abaloparatide/romosozumab:

• Paget disease of bone
• Open epiphyses (pediatric patients)
• Prior skeletal radiation therapy
• Unexplained elevated alkaline phosphatase
• Primary hyperparathyroidism or unresolved secondary hyperparathyroidism 2
• Romosozumab only: Recent MI/stroke or high cardiovascular risk 2

Monitoring Requirements

• Baseline serum calcium before starting (can cause hypercalcemia) 1
• BMD assessment every 1-2 years during and after treatment 2
• Ensure adequate calcium (1000-1200 mg/day) and vitamin D (maintain 25(OH)D ≥30-50 ng/mL) 3

Key Clinical Pitfalls

1. Using bisphosphonates first in very high-risk patients - This delays optimal therapy and reduces subsequent anabolic efficacy 1
2. Failing to transition to antiresorptive after anabolic therapy - Results in rapid bone loss and loss of fracture protection 2, 1
3. Exceeding duration limits - Teriparatide/abaloparatide limited to 2 years lifetime; romosozumab to 12 months 2
4. Stopping denosumab without bridging therapy - High risk of rebound vertebral fractures 1

The evidence strongly supports anabolic-first therapy for patients at very high fracture risk, with immediate transition to antiresorptive consolidation, rather than traditional step-therapy approaches. 1, 2, 3, 6